Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 22, 2021Journal of Clinical MedicineOpen Access

Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment

View Full Paper
Ask AI
Bookmark
Share

Why the study?

The evolution and prognostic value of NT-proBNP and cTnT-HS in ATTR-CA before and after tafamidis treatment needed to be assessed.

Does tafamidis stabilize NT-proBNP and cTnT-HS levels in patients with transthyretin amyloid cardiomyopathy?

Population

454 ATTR-CA patients without tafamidis and 248 ATTR-CA patients with tafamidis

Comparison

Patients treated with tafamidis vs patients without tafamidis

Design

Cohort study

Authors

SOSilvia OghinaHeart Failure & TransplantCJConstant JosseAssociation pour la Recherche en Physiologie de l’EnvironnementMBMélanie BézardHeart Failure & Transplant

Discussion

Loading...

Member takes

Overview

May inform serial biomarker monitoring for ATTR-CA prognosis; leaves open prospective validation before guiding tafamidis decisions.

Structured PICO

Does tafamidis stabilize NT-proBNP and cTnT-HS levels in patients with transthyretin amyloid cardiomyopathy?

P
Population
702 patients with transthyretin amyloid cardiomyopathy (ATTR-CA)
I
Intervention
Tafamidis
C
Comparator
No tafamidis
O
Outcome
Event-free survival (EFS) defined as death, heart transplant, or acute heart failurecomposite

Tafamidis stabilizes NT-proBNP and cTnT-HS levels in ATTR-CA patients, and avoiding a >50% increase in NT-proBNP is associated with improved event-free survival.

Cite This Study

Oghina et al. (2021) studied this question.

synapsesocial.com/papers/6a70d63e8031ec7bb1dc9cc1https://doi.org/10.3390/jcm10214868
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Identification of prognostic markers in transthyretin and AL cardiac amyloidosis*2016 · 77 citations
  2. 2Plasma NT-proBNP levels associated with cardiac structural abnormalities in asymptomatic health examinees with preserved ejection fraction: a retrospective cross-sectional study2019 · 21 citations
  3. 3Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy2018 · 2,859 citations
  4. 4Targeted Therapeutics for Transthyretin Cardiac Amyloidosis2019 · 9 citations
  5. 5Tutorial in Biostatistics: Evaluating the impact of ‘critical periods’ in longitudinal studies of growth using piecewise mixed effects models2001 · 187 citations